Eli Lilly: phase III program initiated in heart failure.

(CercleFinance.com) - Eli Lilly said that along with Germany's Boehringer Ingelheima it has started a clinical phase III programme on empagliflozin for the treatment of adults with chronic heart failure.


The two trials will involve approximately 7,000 patients in all and are expected to be be completed in 2020.

The trials will involve both adults with type-2 diabetes who have heart failure, but also heart failure patients who do not have diabetes.

Approximately 26 million people worldwide suffer from heart failure, which is is the leading cause of hospitalizations in the United States and Europe.

Copyright (c) 2017 CercleFinance.com. All rights reserved.